<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856865</url>
  </required_header>
  <id_info>
    <org_study_id>ADP101-MA-01</org_study_id>
    <nct_id>NCT04856865</nct_id>
  </id_info>
  <brief_title>ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults</brief_title>
  <official_title>A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alladapt Immunotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alladapt Immunotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic&#xD;
      children and adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy and&#xD;
      safety of ADP101 for oral immunotherapy in food allergic children and adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Food Allergy Desensitization</measure>
    <time_frame>Week 40</time_frame>
    <description>The proportion of subjects who tolerate a highest dose of at least 600-mg of protein from a relevant allergen or allergens with no more than mild symptoms at the final/exit double-blind placebo-controlled food challenge.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADP101 vs Placebo Dose Regimen A</intervention_name>
    <description>Active powder formulation at various volumes. Placebo powder formulation at various volumes.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADP101 vs Placebo Dose Regimen B</intervention_name>
    <description>Active powder formulation at various volumes. Placebo powder formulation at various volumes.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 4 to 55 (inclusive)&#xD;
&#xD;
          -  Clinical history of allergy to at least 1 of the foods contained in ADP101&#xD;
&#xD;
          -  Experience dose-limiting symptoms at or below the 100-mg dose level to 1 or multiple&#xD;
             food sources in ADP101&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Experience dose limiting symptoms at or below the 100 mg challenge dose level to more&#xD;
             than 5 food sources contained in ADP101&#xD;
&#xD;
          -  History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock&#xD;
             within 60 days of screening&#xD;
&#xD;
          -  History of EoE, other eosinophilic gastrointestinal disease, chronic, recurrent or&#xD;
             severe GERD, symptoms of dysphagia&#xD;
&#xD;
          -  Severe asthma&#xD;
&#xD;
          -  Mild or moderate asthma, if uncontrolled or difficult to control&#xD;
&#xD;
          -  History of mast cell disorder, including mastocytosis, urticaria pigmentosa or&#xD;
             angioedema&#xD;
&#xD;
          -  History of chronic disease (other than asthma, atopic dermatitis, or allergic&#xD;
             rhinitis) at risk of becoming unstable or requiring a change in chronic therapeutic&#xD;
             regimen e.g. uncontrolled diabetes&#xD;
&#xD;
          -  History of cardiovascular disease, including hypertension requiring &gt; 2&#xD;
             antihypertensive medications&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
&#xD;
          -  History of celiac disease&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment within 3 months&#xD;
&#xD;
          -  Known malignancy that is progressing or has required active treatment within the past&#xD;
             3 years&#xD;
&#xD;
          -  Known history of HIV, known active hepatitis B infection or known active hepatitis C&#xD;
             virus infection&#xD;
&#xD;
          -  Prior/concurrent therapies as follows:&#xD;
&#xD;
               -  beta-blockers, ACE inhibitors, ARBs or calcium channel blockers&#xD;
&#xD;
               -  regular steroid medication use&#xD;
&#xD;
               -  therapeutic antibody treatment currently or within the previous 6 months&#xD;
&#xD;
               -  any food immunotherapy currently or within the previous 12 weeks&#xD;
&#xD;
               -  In the build up phase of non-food immunotherapy&#xD;
&#xD;
          -  Residing at the same address as another subject (e.g. siblings) participating in this&#xD;
             or any other OIT study&#xD;
&#xD;
          -  Develops dose-limiting symptoms to placebo during the Screening DBPCFC&#xD;
&#xD;
          -  Any other condition that might preclude safe participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alladapt Clinical Trial Team</last_name>
    <phone>650-420-3900</phone>
    <email>clinicaltrials@alladapt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Happy Valley</city>
        <state>Oregon</state>
        <zip>97086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alladapt Clinical Trial Team</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADP101</keyword>
  <keyword>Allergy</keyword>
  <keyword>Oral immunotherapy</keyword>
  <keyword>OIT</keyword>
  <keyword>Allergies</keyword>
  <keyword>Food allergies</keyword>
  <keyword>Multi-food allergic</keyword>
  <keyword>Multi-allergen oral immunotherapy</keyword>
  <keyword>Tree nut allergy</keyword>
  <keyword>Milk allergy</keyword>
  <keyword>Wheat allergy</keyword>
  <keyword>Egg allergy</keyword>
  <keyword>Fin fish allergy</keyword>
  <keyword>Shrimp allergy</keyword>
  <keyword>Peanut allergy</keyword>
  <keyword>Sesame seed allergy</keyword>
  <keyword>Soy allergy</keyword>
  <keyword>Shellfish allergy</keyword>
  <keyword>Fish allergy</keyword>
  <keyword>Seafood allergy</keyword>
  <keyword>Dairy allergy</keyword>
  <keyword>Desensitization</keyword>
  <keyword>Food hypersensitivity</keyword>
  <keyword>Immune system disease</keyword>
  <keyword>Hypersensitivity, immediate</keyword>
  <keyword>Hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

